A Rationally Designed Complex Replenishes the Transferrin Iron Pool Directly and with High Specificity.

Many forms of anemia are caused or complicated by pathologic restriction of iron (Fe). Chronic inflammation and certain genetic mutations decrease the activity of ferroportin, the only Fe-exporter protein, so that endogenously recycled or nutritionally absorbed Fe cannot be exported to the extracellular Fe carrier protein transferrin for delivery to the bone marrow. Diminished ferroportin activity renders anemia correction challenging as Fe administered intravenously or through nutritional supplementation is trafficked through the ferroportin-transferrin axis. Utilizing judicious application of coordination chemistry principles, we designed an Fe complex (Fe-BBG) with solution thermodynamics and Fe dissociation kinetics optimized to replenish the transferrin-Fe pool rapidly, directly, and with precision. Fe-BBG is unreactive under conditions designed to force redox cycling and production of reactive oxygen species. The BBG ligand has a low affinity for divalent metal ions and does not compete for binding of other endogenously present ions including Cu and Zn. Treatment with Fe-BBG confers anemia correction in a mouse model of iron-refractory iron-deficiency anemia. Repeated exposure to Fe-BBG did not cause adverse clinical chemistry changes or trigger the expression of genes related to oxidative stress or inflammation. Fe-BBG represents the first entry in a promising new class of transferrin-targeted Fe replacement drugs.

• Publication year

  2023

• Venue

  Journal of the American Chemical Society

• Publication date

  2023-03-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jacs.3c00123PMID 36920018PMCID PMC10312995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• HIF-PHIs for Anemia Management in CKD: Potential and Uncertainty ASCEND.

  2022cited by this paper
• A small molecule redistributes iron in ferroportin-deficient mice and patient-derived primary macrophages

  2022cited by this paper
• Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?

  2022cited by this paper
• Extracellular Cu2+ pools and their detection: From current knowledge to next-generation probes

  2021cited by this paper
• Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease Improving Global Outcomes (KDIGO) Conference.

  2021cited by this paper
• Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease.

  2021cited by this paper
• Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial

  2021cited by this paper
• Applications for Transition-Metal Chemistry in Contrast-Enhanced Magnetic Resonance Imaging.

  2020cited by this paper
• Rational Ligand Design Enables pH Control over Aqueous Iron Magnetostructural Dynamics and Relaxometric Properties.

  2020cited by this paper
• Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms

  2020cited by this paper
• A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the Anemia of Chronic Disease.

  2020cited by this paper
• Liver Iron Retention Estimated from Utilization of Oral and Intravenous Radioiron in Various Anemias and Hemochromatosis in Humans

  2020cited by this paper
• Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

  2019cited by this paper
• Anemia of Inflammation.

  2019cited by this paper
• Ferric pyrophosphate citrate: interactions with transferrin

  2018cited by this paper
• Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

  2018cited by this paper
• Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation.

  2018cited by this paper
• Modern iron replacement therapy: clinical and pathophysiological insights

  2017cited by this paper
• Iron transport proteins: Gateways of cellular and systemic iron homeostasis

  2017cited by this paper
• Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals

  2017cited by this paper
• Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study

  2016cited by this paper
• Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers

  2016cited by this paper
• Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.

  2016cited by this paper
• A simple practice guide for dose conversion between animals and human

  2016cited by this paper
• Pharmacological Targeting of the Hepcidin/Ferroportin Axis

  2016cited by this paper
• Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies

  2014cited by this paper
• EHPG iron(III) complexes as potential contrast contrast agents for MRI.

  2014cited by this paper
• Erythropoietin and Cancer: The Unintended Consequences of Anemia Correction

  2014cited by this paper
• Binding of transition metal ions to albumin: sites, affinities and rates.

  2013cited by this paper
• A hepcidin lowering agent mobilizes iron for incorporation into red blood cells in an adenine-induced kidney disease model of anemia in rats.

  2013cited by this paper
• Thrombotic complications of erythropoiesis-stimulating agents.

  2010cited by this paper
• Detection, evaluation, and management of iron-restricted erythropoiesis.

  2010cited by this paper
• Detailed spectroscopic, thermodynamic, and kinetic studies on the protolytic equilibria of Fe(III)cydta and the activation of hydrogen peroxide.

  2009cited by this paper
• Iron(III) citrate speciation in aqueous solution.

  2009cited by this paper
• The erythropoietin receptor in normal and cancer tissues.

  2008cited by this paper
• Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA)

  2008cited by this paper
• Intrinsic fluorescence reports a global conformational change in the N-lobe of human serum transferrin following iron release.

  2007cited by this paper
• Evaluation of Chemical Amendments for pH and Redox Stabilization in Aqueous Suspensions of Three California Soils

  2007cited by this paper
• Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

  2006cited by this paper
• Correction of anemia with epoetin alfa in chronic kidney disease.

  2006cited by this paper
• Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

  2004cited by this paper
• The Kinetics and Mechanism , of Iron ( II 1 ) Exchange between Chelates and Transferrin

  2003cited by this paper
• Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

  2003cited by this paper
• NTA and Fe(III)NTA: differential patterns of renal toxicity in subchronic studies

  2002cited by this paper
• The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.

  2000cited by this paper
• Intensification and depletion of specific bulky renal DNA adducts (I-compounds) following exposure of male F344 rats to the renal carcinogen ferric nitrilotriacetate (Fe-NTA).

  1995cited by this paper
• Synthesis of N-hydroxybenzylethylenediamine-N,N′,N′-triacetic acid and the stabilities of its complexes with divalent and trivalent metal ions

  1995cited by this paper
• THE IRON(III) AND IRON(II) COMPLEXES OF NITRILOTRIACETIC ACID

  1994cited by this paper
• Oxidative DNA damage, lipid peroxidation and nephrotoxicity induced in the rat kidney after ferric nitrilotriacetate administration.

  1990cited by this paper
• Affinities of racemic and meso forms of N,N'-ethylenebis[2-(o-hydroxyphenyl)glycine] for divalent and trivalent metal ions

  1989cited by this paper
• The induction of autoxidative tissue damage by iron nitrilotriacetate in rats and mice.

  1988cited by this paper
• Nephrotoxicity of ferric nitrilotriacetate. An electron-microscopic and metabolic study.

  1986cited by this paper
• Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site.

  1984cited by this paper
• Thermodynamic binding constants for gallium transferrin.

  1983cited by this paper
• Turnover in the transferrin iron pool during the hypoferremic phase of experimental Neisseria meningitidis infection in mice

  1983cited by this paper
• Electronic Structure of Oxo-Bridged Iron(III) Dimers

  1972cited by this paper
• Fluorescence and absorption studies of the binding of copper and iron to transferrin.

  1969cited by this paper
• The kinetics and mechanism of iron (3) exchange between chelates and transferrin. I. The complexes of citrate and nitrilotriacetic acid.

  1967cited by this paper

• Unique performance of coordination chemistry in food quality control: molecular recognition, sensors and intelligent regulation

  2026cites this paper
• Iron Homeostasis Regulating Glycopeptide Hydrogel Reprograms the Healing Process of Diabetic Wounds Infected With MRSA

  2025cites this paper
• Macrocyclic complexes of Fe(iii) with mixed hydroxypropyl and phenolate or amide pendants as T1 MRI probes

  2024cites this paper
• An octahedral coordination cage with six Fe(iii) centers as a T1 MRI probe

  2024cites this paper
• Fe(III) T1 MRI Probes Containing Phenolate or Hydroxypyridine-Appended Triamine Chelates and a Coordination Site for Bound Water.

  2023cites this paper